Comparison
3 Methylglutaconic Aciduria Type Viia C5676967 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria Type Viia and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viia C5676967
A rare inherited metabolic disorder affecting mitochondrial function. It typically appears in infancy with developmental delay, movement problems, and muscle weakness. Management focuses on supportive care and addressing specific symptoms.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viia C5676967
0-2
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viia C5676967
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viia C5676967
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viia C5676967
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viia-C5676967 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Developmental delay | Often begins in infancy with motor delay and weakness. | Developmental and learning challenges may be recognized in childhood. | Moderate |
| Movement and muscle findings | Movement problems and muscle weakness are described. | Not a defining feature in the supplied description. | Moderate |
| Facial appearance | No distinctive facial pattern is established here. | Distinctive facial features are often reported. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viia C5676967 when
Infant with delay, weakness, and suspected metabolic disease
The supplied profile points to an inherited mitochondrial disorder.
Moderate
Abnormal organic-acid pattern suggesting 3-methylglutaconic aciduria
This supports the named metabolic finding, not a chromosomal diagnosis.
Moderate
Severe early neuromuscular course
Source severity is severe, but diagnosis still needs confirmation.
Low
Choose 17p11 2 Microduplication Syndrome C2931246 when
Developmental delay with learning difficulty and facial features
This pattern fits the supplied chromosomal syndrome description.
Moderate
Microarray shows 17p11.2 duplication
A confirmed duplication supports Potocki-Lupski-related diagnosis.
High
No metabolic crisis or organic-acid abnormality
Absence of metabolic clues makes the chromosomal condition more plausible.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid; cutoff not specified. | No characteristic organic-acid abnormality is established. | An abnormal result is a clue, not a complete diagnosis. |
| Chromosomal microarray | Not expected to identify this metabolic disorder. | May detect a 17p11.2 microduplication. | Genetic confirmation should be interpreted by a clinician. |
| Mitochondrial or gene testing | May be considered to confirm the inherited metabolic cause. | Not the primary test when duplication is already confirmed. | Test choice depends on phenotype and prior results. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viia C5676967
- Outcome
- Often severe and chronic, but individual outcome is not established.
- Factors
- Age at onset, neurologic involvement, and confirmed metabolic diagnosis.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Often moderate and chronic, with variable learning needs.
- Factors
- Duplication confirmation, developmental profile, and available supports.
Time frame: From infancy or early childhood into long-term follow-up.
Prognosis should be individualized; mortality and exact trajectories are not supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Delay, movement problems, and weakness may be prominent. Developmental and learning challenges are emphasized. Severity and course vary; exact outcomes are not established. |
| Feeding or growth difficulty | Possible with early neuromuscular weakness, but not quantified. May occur in some children; frequency is not supplied. Monitor individually rather than assuming a fixed complication. |
| Medical complexity | Severe metabolic disease may need multidisciplinary support. Moderate congenital condition often needs developmental support. Neither description establishes mortality or treatment doses. |
Patient education highlights
- HighDifferent causes
One is a rare metabolic disorder; the other is a chromosomal duplication. Testing, not symptoms alone, distinguishes them.
- HighSupportive care
Management is individualized and supportive. No dose or definitive treatment should be inferred from this comparison.
- MediumFamily implications
Inheritance and recurrence risk differ by confirmed diagnosis and should be reviewed with genetics.